Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 11/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 11/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16092649 | 1.00 | PTGER4 (0.38) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL16088695 | 1.00 | PTGER4 (0.38) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL18948465 | 0.80 | PTGER4 (0.34) | PTGER4PTGER3PTGER2 | |
| SCHEMBL15258191 | 0.75 | PTGER4 (0.44) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL16092706 | 0.75 | PTGER4 (0.35) | PTGER4PTGER3PTGER2 | |
| SCHEMBL17548575 | 0.74 | PTGER4 (0.48) | PTGER4PTGER3PTGER2 | |
| SCHEMBL17487079 | 0.74 | PTGER4 (0.48) | PTGER4PTGER3PTGER2 | |
| SCHEMBL15258196 | 0.73 | PTGER4 (0.49) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL15258194 | 0.73 | PTGER4 (0.49) | PTGER4PTGER3PTGER2KCNH2 | |
| SCHEMBL15258189 | 0.73 | PTGER4 (0.47) | PTGER4PTGER3PTGER2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3235817-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | Cayman Chemical Company, Incorporated (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2989098-B1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL CO INC (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2014144610-A1 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144584-A2 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS | CAYMAN CHEMICAL COMPANY, INC. (US) | 2014-09-18 | — | — | WO | disclosed |